Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
5.12
+0.04 (0.79%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Lifecore Biomedical Revenue
In the year 2025, Lifecore Biomedical had annual revenue of $129.46M with 0.46% growth. Lifecore Biomedical had revenue of $35.75M in the quarter ending December 31, 2025, with 9.77% growth.
Revenue (ttm)
$129.46M
Revenue Growth
+0.79%
P/S Ratio
1.48
Revenue / Employee
$338,913
Employees
382
Market Cap
191.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 129.46M | 597.59K | 0.46% |
| May 25, 2025 | 128.87M | 606.00K | 0.47% |
| May 26, 2024 | 128.26M | 24.99M | 24.20% |
| May 28, 2023 | 103.27M | -8.00M | -7.19% |
| May 29, 2022 | 111.27M | 10.40M | 10.31% |
| May 30, 2021 | Pro | Pro | Pro |
| May 31, 2020 | Pro | Pro | Pro |
| May 26, 2019 | Pro | Pro | Pro |
| May 27, 2018 | Pro | Pro | Pro |
| May 28, 2017 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 564.17M |
| Evolus | 297.18M |
| Aurora Cannabis | 272.13M |
| Akebia Therapeutics | 236.20M |
| Organigram Global | 204.21M |
| Assertio Holdings | 118.71M |
| Anika Therapeutics | 112.82M |
| SIGA Technologies | 94.57M |
LFCR News
- 6 days ago - Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit - GlobeNewsWire
- 4 weeks ago - Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer - GlobeNewsWire
- 5 weeks ago - Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company - GlobeNewsWire
- 6 weeks ago - Lifecore Biomedical Transcript: 2026 KeyBanc Capital Markets Healthcare Forum - Transcripts
- 6 weeks ago - Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 6 weeks ago - Lifecore Biomedical Transcript: Transition period - Transcripts
- 6 weeks ago - Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update - GlobeNewsWire